Addressing the COVID-19 Pandemic
The Biocon Group addressed the COVID-19 pandemic unitedly with undeterred spirit and unwavering purpose.
The Biocon Group addressed the COVID-19 pandemic unitedly with undeterred spirit and unwavering purpose.
Despite the capital-intensive nature of insulin production, Biocon has succeeded in expanding access to insulin therapy in India and key global markets by pursuing an innovation strategy that is rooted in affordability.